Clinical Trials Directory

Trials / Completed

CompletedNCT03899285

Citalopram Titration in Early Non-responder Patients With Major Depressive Disorders

Citalopram Titration in Early Non-responder Patients With Major Depressive Disorders: a Pilot Study (CRY-MOOD)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
8 (actual)
Sponsor
Ciusss de L'Est de l'Île de Montréal · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Major depressive disorder is a common mental disorder and the leading cause of disability worldwide. According to the Canadian Network for Mood and Anxiety Treatment, early improvement following an antidepressant treatment is correlated with response and remission. Escalation of an antidepressant dose after 2 weeks, as opposed to 4 to 8 weeks, is proposed to favor early improvement. However, this has never been tested systematically in a controlled study involving major depressive disorder patients that are non-responders to their antidepressant treatment.

Detailed description

The investigators sought to assess whether it is feasible to perform a prospective randomized controlled double-blind feasibility study with a 2 week run-in period and 3 parallel groups randomized controlled study using citalopram. Citalopram has physicochemical properties compatible with over-encapsulation and a has a simple titration that allows the study of early dose increase.. It is among the most prescribed antidepressant in the province of Quebec and at the Hospital Maisonneuve-Rosemont - University family medicine group (U-FMG). Since establishment of a randomized controlled trial is complex and expensive, a feasibility design is appropriate to identify all the obstacles and to minimize sources of possible bias (recruitment, follow up, resources).

Conditions

Interventions

TypeNameDescription
DRUGCitalopram 20mg or 40 mg (phase 2)For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.

Timeline

Start date
2018-01-08
Primary completion
2018-12-08
Completion
2018-12-08
First posted
2019-04-02
Last updated
2019-04-04

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03899285. Inclusion in this directory is not an endorsement.